Discover how a newly developed platform technology from The University of North Carolina at Chapel Hill can enhance RNAi ...

The Indian Council of Medical Research is fast-tracking an experimental RNA-based antiviral therapy for Chikungunya, inviting ...

Key market opportunities in the RNA Therapy Clinical Trials sector include an increase in chronic and rare diseases, advancements in delivery technologies like lipid nanoparticles, robust venture ...

Benitec Biopharma Inc. reports 100% responder rates for BB-301 with a mid-2026 FDA meeting ahead. See why BNTC stock is upgraded to buy.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the best healthcare stocks to buy for 2026. On January 20, RBC Capital reiterated an Outperform rating on Alnylam Pharmaceuticals, Inc.

Scientists have uncovered a 400-million-year-old genetic secret that gave spiders the ability to produce silk and weave their ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 5, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s investigational RNA interference (RNAi ...

The therapy is designed to silence both PCSK9 and APOC3 genes simultaneously.

• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with ...

Some scientists who argue for deregulation deny outdoor gene editing is possible. But patents and the scientific literature ...

Following the hard-won success of early anti-amyloid drugs, a new generation of Alzheimer’s modalities—from tau-targeting ...